Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review).
暂无分享,去创建一个
M. Pantaleo | M. Nannini | A. Maleddu | G. Biasco | Margherita Nannini | Maristella Saponara | Guido Biasco | C. Lolli | M. Di Battista | M. Saponara | Maria A Pantaleo | Alessandra Maleddu | Monica Di Battista | Cristian Lolli
[1] Y. Matsuzawa,et al. c‐kit Gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors , 2003, Journal of gastroenterology and hepatology.
[2] M. Ladanyi,et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] A. D. Van den Abbeele,et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] C. Tzen,et al. Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors , 2008, Medical oncology.
[5] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[6] J. Desai,et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Debiec‐Rychter,et al. Cellular Uptake of the Tyrosine Kinase Inhibitors Imatinib and AMN107 in Gastrointestinal Stromal Tumor Cell Lines , 2006, Pharmacology.
[8] P. Marynen,et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. , 2005, Gastroenterology.
[9] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[10] C. Antonescu,et al. Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation , 2005, Clinical Cancer Research.
[11] C. Antonescu,et al. Results of Tyrosine Kinase Inhibitor Therapy Followed by Surgical Resection for Metastatic Gastrointestinal Stromal Tumor , 2007, Annals of surgery.
[12] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.
[13] Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation , 2004, British Journal of Cancer.
[14] P. Seeburg,et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.
[15] H. Serve,et al. A Single Amino Acid Exchange Inverts Susceptibility of Related Receptor Tyrosine Kinases for the ATP Site Inhibitor STI-571* 210 , 2003, The Journal of Biological Chemistry.
[16] S. Hirota,et al. Gain-of-Function Mutations of Receptor Tyrosine Kinases in Gastrointestinal Stromal Tumors. , 2006, Current genomics.
[17] S. Hirota,et al. Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib‐resistant gastrointestinal stromal tumor , 2008, Cancer science.
[18] J. Lasota,et al. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours , 2008, Histopathology.
[19] M. Fukayama,et al. Mutations in c‐kit Gene Exons 9 and 13 in Gastrointestinal Stromal Tumors among Japanese , 2001, Japanese journal of cancer research : Gann.
[20] C. Antonescu,et al. Rhabdomyosarcomatous Differentiation in Gastrointestinal Stromal Tumors After Tyrosine Kinase Inhibitor Therapy: A Novel Form of Tumor Progression , 2009, The American journal of surgical pathology.
[21] P. Schnyder,et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[22] E. van den Berg,et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] T. Nishida,et al. Gain‐of‐function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours , 2001, The Journal of pathology.
[24] J. Fletcher,et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] A. D. Van den Abbeele,et al. Clonal Evolution of Resistance to Imatinib in Patients with Metastatic Gastrointestinal Stromal Tumors , 2007, Clinical Cancer Research.
[26] D. Flieder,et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors , 2008, Proceedings of the National Academy of Sciences.
[27] Samuel Singer,et al. PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.
[28] S. Hirota,et al. A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. , 1998, Gastroenterology.
[29] M. Heinrich,et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Munir Pirmohamed,et al. Active transport of imatinib into and out of cells: implications for drug resistance. , 2004, Blood.
[31] J. Fowler,et al. Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec). , 2007, Nuclear medicine and biology.
[32] L. Sobin,et al. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. , 2000, The American journal of pathology.
[33] Qimin He,et al. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. , 2003, Cancer research.
[34] J. Blay,et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. , 2005, European journal of cancer.
[35] J. Fletcher,et al. Biology of gastrointestinal stromal tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] J. Fletcher,et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST , 2008, The Journal of pathology.
[37] M. Pirmohamed,et al. Expression of the Uptake Drug Transporter hOCT1 is an Important Clinical Determinant of the Response to Imatinib in Chronic Myeloid Leukemia , 2008, Clinical pharmacology and therapeutics.
[38] J. Fletcher,et al. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway , 2007, Oncogene.
[39] A. D. Van den Abbeele,et al. The Lessons of GIST — PET and PET / CT : A New Paradigm for Imaging , 2008 .
[40] M. Pirmohamed,et al. hOCT 1 and resistance to imatinib. , 2005, Blood.
[41] M. van Glabbeke,et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. , 2004, European journal of cancer.
[42] Angela Greco,et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. , 2004, Gastroenterology.
[43] Wei Zhang,et al. A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal Tumors , 2004, Cancer Research.
[44] S. Hirota,et al. Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. , 2002, Gastroenterology.
[45] J Nuyts,et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). , 2003, European journal of cancer.
[46] C. Antonescu,et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] P. Casali,et al. Surgery of Residual Disease Following Molecular-targeted Therapy With Imatinib Mesylate in Advanced/Metastatic GIST , 2007, Annals of surgery.
[48] E. Wardelmann,et al. Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients , 2007, Gastric Cancer.
[49] C. J. Chen,et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. , 2001, Cancer research.
[50] Kazuhiro Yoshida,et al. Deletion of the KIT gene is associated with liver metastasis and poor prognosis in patients with gastrointestinal stromal tumor in the stomach. , 2006, International journal of oncology.
[51] Derek Y. Chiang,et al. Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.
[52] C. Nanni,et al. What oncologists need and require from nuclear medicine , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[53] D. Goldstein,et al. Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour. , 2005, The Lancet. Oncology.
[54] T. Utsunomiya,et al. Secondary c-kit Mutation in a Recurrent Gastrointestinal Stromal Tumor Under Long-Term Treatment with Imatinib Mesylate: Report of a Case , 2007, Surgery Today.
[55] M. Ferrone,et al. Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients , 2006, Oncogene.
[56] F. Bertucci,et al. Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour. , 2006, Oncology reports.
[57] E. Wardelmann,et al. Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate , 2006, Clinical Cancer Research.
[58] N. Socci,et al. Gene Expression in Gastrointestinal Stromal Tumors Is Distinguished by KIT Genotype and Anatomic Site , 2004, Clinical Cancer Research.
[59] Peter Hohenberger,et al. 68Ga-Labeled Bombesin Studies in Patients with Gastrointestinal Stromal Tumors: Comparison with 18F-FDG , 2007, Journal of Nuclear Medicine.
[60] K. Wilson,et al. Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase* , 2004, Journal of Biological Chemistry.
[61] M. Pierotti,et al. KIT/Val654 Ala receptor detected in one imatinib-resistant GIST patient. , 2005, Cancer research.
[62] A. B. Lyons,et al. Resistance to c-KIT kinase inhibitors conferred by V654A mutation , 2007, Molecular Cancer Therapeutics.
[63] Narasimhan P. Agaram,et al. Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors , 2007, Clinical Cancer Research.
[64] Xin Huang,et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.
[65] H. Garewal,et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors , 2007, Oncogene.
[66] A. Schinkel,et al. Polymorphisms affecting function of the human organic cation transporter hOCT1 (SLC22A1): what are the consequences? , 2002, Pharmacogenetics.
[67] J. Fletcher,et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. , 2000, The American journal of pathology.
[68] Amir Kashefi,et al. A new PET tracer specific for vascular endothelial growth factor receptor 2 , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[69] J. Vermeesch,et al. Array CGH analysis in primary gastrointestinal stromal tumors: Cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status , 2007, Genes, chromosomes & cancer.